Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciccolini, J.
Right arrow Articles by Catalin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciccolini, J.
Right arrow Articles by Catalin, J.
Clinical Cancer Research Vol. 6, 1529-1535, April 2000
© 2000 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Enhanced Antitumor Activity of 5-Fluorouracil in Combination with 2'-Deoxyinosine in Human Colorectal Cell Lines and Human Colon Tumor Xenografts1

Joseph Ciccolini2, Laurent Peillard, Alexandre Evrard, Pierre Cuq, Claude Aubert, André Pelegrin, Patricia Formento, Gérard Milano and Jacques Catalin

Laboratoire de Toxicocinetique et Pharmacocinetique, Faculté de Pharmacie, Marseille Cedex 05, France [J. Ci., L. P., C. A., J. Ca.]; Laboratoire de Toxicologie, Faculté de Pharmacie, 34000 Montpellier, France [A. E., P. C.]; CRLC Val D’aurelle, 34000 Montpellier, France [A. P.]; and Laboratoire d’Oncopharmacologie, Centre A. Lacassagne, 06000 Nice, France [P. F., G. M.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We investigated the effects of 2'-deoxyinosine (d-Ino), a modulator yielding thymidine phosphorylase activity, on cellular pharmacology of 5-fluorouracil (FUra) in various human colorectal cell lines and its antitumoral activity when combined with FUra in human xenografts. Associating d-Ino with FUra increased by 38 up to 700 times the sensitivity of HT29 and FUra-resistant SW620 lines, respectively, but not of CaCo2 cells, although high levels of intracellular FdUMP and subsequent higher thymidylate synthase inhibition were observed. Cell death studies confirmed the ability of d-Ino to enhance both early and late apoptosis induced by FUra in HT29 and SW620 but not in CaCo2. Similarly, we showed that associating d-Ino increased by 68 up to 101% the Fas overexpression induced by FUra in HT29 and SW620 but not in CaCo2 cells. Anti-Fas and anti-FasL antibodies both partly reversed this increase of cell sensitivity, thus confirming the role Fas plays in the modulation of FUra toxicity by d-Ino. This Fas component could explain the discrepancy between the lines because CaCo2 has been described as insensitive to Fas-mediated apoptosis. Antitumor activity of the combination was next investigated in nude mice transplanted with SW620. Results showed that although FUra alone has little effect on SW620 xenografts (P > 0.05), associating d-Ino significantly reduced the tumor growth by 57% (P < 0.05). This study suggests that it is possible to reduce both in vitro and in vivo resistance to FUra by modulating the way the drug is converted after cellular uptake.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Forty years after its synthesis (1) , FUra3 remains a mainstay in the treatment of colorectal cancer. However, because the overall response rate does not exceed 20% (2) , improving FUra efficacy is still a major concern of today’s chemotherapy. Because FUra antiproliferative activity depends on its intracellular conversion to FdUMP, fluorodeoxyuridine triphosphate, and FUTP interfering with TS, DNA, and RNA, respectively (3, 4, 5) , attempts to control and predict FUra activation have been described extensively (6) . Recent studies underlined the key role TP could play in FUra metabolism. Increasing TP activity includes the use of IFN-{alpha} and IFN-{gamma} (7, 8, 9) , pyrimidine analogues (10) , or direct transfer of the TP gene (11, 12, 13, 14) . This new trend in FUra modulation led us to investigate the effects of d-Ino, a deoxyribose 1-phosphate precursor, the ability of which to potentiate FUra cytotoxicity was reported in the late 1960s and 1970s (7, 8, 9) . The purpose of this present work is to further study to what extent d-Ino can affect FUra cellular pharmacology in various human colorectal cell lines, to elucidate the mechanism by which cell death is augmented by this association, and finally to assess the possible use of this combination in human xenografts models.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
HT29, SW620, and CaCo2 human colon carcinoma cell lines were kindly provided by Prof. Barra (UPRES A CNRS 6032, Marseille, France). Cells were maintained in DMEM supplemented with 10% FCS (CaCo2: 12%), 1% glutamine (CaCo2: 2%), 110 IU penicillin/ml, 100 µg streptomycin/ml, and 50 µg kanamycin/ml in a humidified CO2 incubator at 37°C.

Drugs and Chemicals.
[6-3H]-FUra (12.6 Ci/mmol) came from DuPont NEN (Les Ulis, France), [3H]thymine (40 Ci/mmol) was provided by Isotopchim (Ganagobie, France), and [3H]dUMP (16 Ci/mmol) was from Moravek Biochemicals (Brea, CA, USA). All other chemicals were purchased from Sigma Chemical Co. (St. Quentin Fallavier, France). Anti-Fas ZB4 and CH11 and anti-FasL 4A5 MoAbs were provided by Immunotech (Marseille, France).

Antiproliferative Assays.
Exponentially growing cells were exposed in 96-well plates to increasing concentrations of FUra, alone or combined with 1 mM d-Ino. Anti-CD95 ZB4 (500 ng/ml) and anti-FasL 4A5 (1000 ng/ml) MoAbs were added when indicated. The IC50 was defined as the FUra concentration inhibiting 50% of the cell growth. Control cells were incubated with d-Ino or MoAbs when the latter were used in the experiments. After 72 h of continuous exposure, cell growth was evaluated using the classic colorimetric 3-(4,5-dimethyltriazol-2-yl)-2,5-diphenyltetrazolium bromide assay (15) .

Determination of [3H]FUra Intracellular Metabolites.
Separation and detection of [3H]FUra metabolites were performed as described previously (14) . Exponentially growing cells were exposed to various combination of 100 µCi of tritiated FUra (final concentration 2 µM) alone or associated with 600 µM of d-Ino for time intervals ranging from 0.5 up to 72 h. Cells were harvested, and cytosols were isolated for HPLC analysis. The HPLC consisted of a HP 1090 (Hewlett Packard) system coupled to a A200 radioactive flow detector (Packard). Separation of tritiated metabolites was achieved using a Lichrospher 100 RP18 5 µm column (Hewlett Packard) eluted by 50 mM K2HPO4 (pH 6.8) containing 5 mM tetrabutyl ammonium nitrate and 12% (0–9 min) to 16% (9–60 min) methanol.

Determination of dTTP DNA Incorporation.
Cells were exposed to 50 µCi of tritiated thymine (final concentration 0.5 µM) with or without 1 mM d-Ino for 1, 24, and 48 h. Cells were then treated as described in "Determination of [3H]FUra Metabolites." After centrifugation at 18,000 x g for 30 min, supernatant was discarded, and pellet was resuspended in 60% methanol and counted for radioactivity by liquid scintillation counting (Beckman).

TS Activity.
TS activity was assessed as described previously (16) . Briefly, exponentially growing cells were exposed to various combinations of FUra alone or associated with 1 mM d-Ino. Inhibition of TS activity was evaluated after two exposition schedules: a short exposition time (5 h) to high-dose FUra (~10 times the respective IC50) and a long exposition (72 h) with a normal dose (IC50). Cells were then harvested, and pellet was stored at -80°C until analysis. TS activity was assayed following the standard Roberts method based on tritiated H2O release from [3H]dUMP in the presence of excess of methylene tetrahydrofolate (17) .

Apoptosis Studies.
Cells in exponential phase were exposed to d-Ino (1 mM), FUra (0.5 µM), or a combination of both for 48 h. Cells were then harvested; early apoptotic changes and late apoptosis were detected by simultaneous staining with Annexin V and propidium iodide using Annexin V FITC staining kit (Euromedex, Souffelweyersheim, France). Cells were treated following the manufacturer’s guideline. FACS analysis was carried out in a FACScan flow cytometer (Becton Dickinson) using Cell Quest Software. Apoptosis measured in untreated cells was defined as 100%.

Detection of the CD95 (APO1-fas) Receptor.
Exponentially growing cells were exposed to 0.5 µM of FUra alone or combined with 1 mM d-Ino for 72 h. Cells were then trypsinized, washed, and exposed to 4 ng/µl of CH11 anti-Fas MoAb for 45 min at 4°C. After two washing steps, cells were resuspended in DMEM containing 1:200 (v/v) goat antimouse IgM (Immunotech, Marseille, France) and incubated for an additional 30 min at 4°C. Cells were then washed twice, and cell surface expression of the CD95 was assessed by FACScan. Analysis was carried out in a FACScan flow cytometer using Cell Quest Software. Cells exposed to goat antimouse IgM only served as negative FITC control. Relative Fas expression was defined as the ratio of fluorescence CH11 Fas MoAb:isotype-matched negative control MoAb. Relative Fas expression in untreated cells was considered as 100%.

In Vivo Studies.
The antitumor effect of FUra combined with d-Ino was investigated in the SW620 mouse xenograft model. Swiss nude mice (Iffa Credo, L’Arbresles, France) were s.c. transplanted with fragments of SW620 harvested from s.c. growing tumors in nude mice. Mice care was in agreement with animal welfare guidelines. To avoid unnecessary use of animals, a prior experiment (saline versus d-Ino) was first carried out to assess the tolerance of high-dose d-Ino alone in SW620-bearing mice and its possible effect on tumor growth. The second part of the experiment (saline versus FUra versus FUra + d-Ino) started only after in vivo effects of high dose d-Ino alone had been fully evaluated. Animals (n = 10) were administered either saline (i.p.), d-Ino (1.6 g/kg, twice daily i.p.), FUra (35 mg/kg, daily i.p.) or a combination of both for 5 days Treatments started after tumors became measurable, usually by day 11. Tumor growth was measured three times a week in three dimensions, and tumor weight (mg) was assessed using an established formula: weight (mg) = [width (mm) x length (mm) x thickness (mm)]/2. The experiment was terminated when tumors in control animals reached a size of ~1.5 g.

Statistical Analysis.
Differences between mean values were evaluated using either one-way ANOVA with Tukey test or one-way ANOVA on Ranks with Dunnetts or Student-Newman-Keuls test, according to data distribution. P = 0.05 was regarded as statistically significant. Tumor weights at study conclusion were analyzed using one-way ANOVA with multiple comparison Tukey tests to determine which groups were different from each other. The Student t test was carried out for checking the absence of tumoral effect of d-Ino alone versus control in the prior experiment. All analyses were performed using Sigma Stat software (Jandel Scientific).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Modulation of Antiproliferative Activity
Results of cytotoxic studies are summarized in Table 1Citation . Associating high dose d-Ino to FUra significantly increased HT29 and SW620 sensitivity by 38 and 700 times, respectively. Conversely, using d-Ino did not improve FUra cytotoxic activity in CaCo2. The increase of Fura toxicity in HT29 cells by d-Ino was reduced to eight times by ZB4 MoAb, and totally reversed when 4A5 MoAb was associated with the drugs. Similarly, ZB4 and 4A5 MoAbs reduced from 730 down to 21 and 9 times, respectively, the d-Ino enhancement of SW620 sensitivity to FUra.


View this table:
[in this window]
[in a new window]

  		Table 1 Modulation of 5-FUra antiproliferative activity by d-Ino +/- anti-Fas and anti-FasL MoAbs

 
Modulation of Intracellular Activation
HPLC analysis performed on cytosols of HT29, SW620, and CaCo2 cells exposed to [3H]FUra for various incubation times showed that the main activation pathway of the drug led to the formation of 5-fluorouridine, fluorouridine monophosphate, FUDP, and FUTP metabolites. Using d-Ino induced a switch of the FUra activation from the RNA to the DNA pathway, with FdUrd, FdUMP, fluorodeoxyuridine diphosphate, and fluorodeoxyuridine triphosphate metabolites being then detected in the different lines we tested. This complete reversal in the activation pathway was constant throughout time up to 72 h, although FdUrd and FdUMP peaked for the shorter incubation times only (Fig. 1)Citation .



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Monitoring of [3H]FUra conversion to nucleosides and nucleotide monophosphate in SW620 cells. Cells were exposed to 2 µM tritiated FUra alone (A) or combined with 600 µM d-Ino (B) for 1–72 h. Cytosols were analyzed by HPLC, as described in "Materials and Methods." Values are from one representative experiment.

 
[3H]dTTP DNA Incorporation
We monitored [3H]thymine DNA incorporation as a marker of TP activity in whole cells. Incubating the cells with d-Ino induced a greater dTTP incorporation throughout time in all of the lines we tested. dTTP nuclear incorporation was potentiated by 13, 207, and 126 times (after 1, 24, and 48 h, respectively) in HT29 cells (P < 0.05; one-way ANOVA on ranks with Student-Newman-Keuls testing); 15, 22, and 8 times in SW620 cells (P < 0.05); and 11, 3, and 6 times in CaCo2 cells (P < 0.05).

TS Inhibition
FUra alone showed a marked effect on TS activity. However, associating d-Ino augmented TS inhibition in the different cell lines according to the exposition schedule. TS activity was inhibited by 78% (HT29), 95% (SW620), and 96% (CaCo2) after exposition to high-dose FUra for 5 h, whereas a total inhibition (100%) was observed in the different lines when d-Ino was associated to the drug. TS inhibition after 72-h exposure to lower doses of FUra was 48% (HT29), 75% (SW620), and 58% (CaCo2); combining d-Ino improved up to 81% (HT29), 99% (SW620), and 86% (CaCo2) the TS-directed action of the fluoropyrimidine (Fig. 2)Citation .



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Enhancement of FUra- induced TS inhibition by d-Ino. Cells were exposed to high-dose FUra for 5 h (A) or low-dose 5-FU for 72 h (B). {square}, untreated cells; , FUra; {blacksquare}, FUra + 1 mM d-Ino. Values are means of three separate experiments; bars, SD. a, P < 0.05, one-way ANOVA; b, Dunnett’s test; bld, below the limit of detection.

 
Apoptosis Studies
Results of detection of apoptosis are summarized in Fig. 3Citation . A greater induction of both early and late apoptosis was observed in HT29 and SW620 exposed to FUra combined with d-Ino, compared with FUra alone. Enhancement of FUra-induced apoptosis when d-Ino was associated ranged from 19 to 130% (late/early), respectively, in HT29 cells and from 210 to 497% in SW620. Conversely, no increase of apoptosis was detected in CaCo2 (1.7% to 9%) exposed to the association compared with cell death caused by FUra alone.



View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Enhancement of FUra-induced apoptosis by d-Ino. HT29 (A), SW620 (B), and CaCo2 (C) cells were exposed to either 1 mM d-Ino, 0.5 µM 5-FU, or a combination of both for 48 h. Early ({square}) and late () apoptosis was detected by PI/Annexin V double staining with subsequent flow cytometry analysis. Values are means of three separate experiments. a, P < 0.05, one-way ANOVA with Dunnett’s test.

 
Expression of Fas CD95 Protein
Exposing the cells to FUra alone induced an overexpression of Fas in HT29 (79%) but not in SW620 cells (1%). Associating d-Ino enhances Fas overexpression in HT29 (147%) and triggers Fas in SW620 (103%). On the contrary, we could not detect CD95 protein on the CaCo2 cell surface, whether the cells were exposed to FUra alone or combined with d-Ino because no difference in fluorescence was observed between cells exposed to anti-Fas CH11 MoAb and cells exposed to isotype-matched negative control MoAb only (Fig. 4)Citation .



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Enhancement of FUra-induced Fas expression by d-Ino. HT29 (A), SW620 (B), and CaCo2 (C) cells were exposed to 0.5 µM FUra alone () or combined with 1 mM d-Ino ({blacksquare}) for 72 h and subjected to FACS analysis of cell surface CD95 protein. Relative Fas expression is defined as the ratio mean fluorescence Fas MoAb:FITC control. The ratio obtained for untreated cells ({square}) was considered as 100% of Fas expression. Values are means of five separate experiments; bars, SD. a, P < 0.05, one-way ANOVA on ranks with Dunnett’s test. b, no difference between Fas MoAb and FITC control.

 
In Vivo Studies
Effects of d-Ino Alone on Tumor Growth.
The final tumor weights of mice treated with NaCl (mean, 1520 ± 695 mg) or d-Ino (mean, 1805 ± 580 mg) was not statistically different (P = 0.459; Student’s t test). Moreover, no difference was either observed in animal weights before (NaCl: 21.7 ± 0.7 g, d-Ino: 21.4 ± 1g; P = 0.663; Student’s t test) and by the end of the experiment (NaCl: 23.8 ± 1.4 g, d-Ino: 23.5 ± 1.7 g; P = 0.765; Student’s t test) between the two groups, suggesting that the d-Ino doses used had been well tolerated.

Effects of Combined d-Ino and FUra on Tumor Growth.
ANOVA analysis performed on final tumor weights at day 23 showed that there was a statistical difference between the treatments (P = 0.005). Further multiple comparison testing indicated that combining d-Ino to FUra significantly reduced tumor growth by 57% (P < 0.05; Tukey), whereas FUra alone had little effect (P > 0.05). Evolution of tumor weights is displayed in Fig. 5Citation .



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effects of combination 5-FU + d-Ino on SW620 tumor growth in nude mice. Mice (10 animals/group) were s.c. transplanted with fragments of SW620 tumors and exposed for 5 days to either: {circ}, saline (daily i.p.); {blacktriangleup}, FUra (35 mg/kg, daily i.p.); or {blacksquare}, FUra (35 mg/kg, daily i.p.) + d-Ino (1.6 g/kg, twice daily i.p.). Tumor size was measured three times a week using calipers; values are means; bars, SD. a, P < 0.05, one-way ANOVA with Tukey test.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Several decades after the first use of FUra in colorectal cancer, its metabolism and mechanisms of action are still under scrutiny. According to the predominance of the active metabolites FdUMP, fluorodeoxyuridine diphosphate, and FUTP, FUra can exert its cytotoxic activity by inhibiting TS, interfering with DNA or RNA, respectively (3 , 18) . However, FdUMP is admittedly the main key active metabolite (19 , 20) , although some authors reported that TS may not be always the main locus of action of FUra, essentially in normal tissues (21 , 22) , but in some tumor models as well (23 , 24) . FdUMP formation is under the dependence of various enzymatic activities (25, 26, 27) , but most data suggest its synthesis from FUDP through ribonucleotide reductase (26) . Alternatively, FdUMP could be directly formed from FdUrd after activation of FUra by TP, but this pathway does not seem to be predominant in cells normally exposed to FUra, probably because of the lack of TP cofactor dR1P (28) . However, several reports on FUra modulation by IFN recently highlighted the key role TP could play in FUra activation, suggesting that FUra cytotoxic activity could be enhanced when FdUMP is directly formed through the DNA pathway (11 , 29 , 30) . In a previous work, we showed that transfecting the TP gene to human LS174T colon carcinoma led to an accumulation of intracellular FdUMP. This change of anabolism was accompanied with an 80 times increase in FUra toxicity in transfected cells compared with the parent line (14) . Schwartz et al. (10) screened several pyrimidine analogues for their ability to increase TP activity and to enhance FUra efficacy both in vitro and in vivo, thus suggesting that providing the cells with precursors of dR1P could be a convenient alternative for augmenting TP activity and subsequent FdUMP accumulation. In this present work, we studied the effects when combined with FUra of d-Ino, a purine analogue providing dR1P after phosphorolytic cleavage (31) . Although d-Ino is almost as old as FUra itself (7 , 8 , 29 , 32) , the extent of its effect on FUra cellular pharmacology and induction of apoptosis has not been fully reported yet, nor its possible in vivo use. Using high-dose d-Ino proved to greatly increase TP activity, FdUMP formation, and subsequent TS inhibition in the various cell lines we tested. Yet, although a significant increase of cell sensitization and apoptosis induction was observed in HT29 and SW620 cells, the CaCo2 line appeared to be resistant to the modulation. To understand this disparity, we then studied the cell death signaling occurring after exposition of the cells to the association. We showed an increase of Fas expression in HT29 and SW620 cells exposed to the combination, whereas both anti-Fas and anti-FasL MoAbs reversed, in part, the increase of cell sensitivity. These data suggest strongly a Fas component in the enhancement of FUra apoptosis by d-Ino. This implication of Fas signaling could explain the resistance of CaCo2 to this association, because this line has been described as insensitive to Fas-mediated apoptosis (33 , 34) .

The mechanisms by which FUra causes apoptosis are still not understood completely. It is much likely that the mechanisms underlying cell death induced by fluoropyrimidines are cell type specific and administration schedule dependent. The down-regulation of Bcl2 is associated with an up-regulation of Bax (35) ; augmentation of the p53 protein level (36 , 37) has already been related to FUra-induced apoptosis. Other studies showed that FUra could cause apoptosis via a Fas-dependent pathway but without correlating this Fas overexpression with a particular mechanism of action of the drug (38) . Houghton et al. (34) and Tillman et al. (39) demonstrated recently that thymineless death in colon cancer cells was mediated via Fas. The same isolated later a Fas component in cells treated with FUra modulated by leucovorin and/or IFN-{gamma} (34 , 39) . Our results are consistent with these latest findings, because we showed that associating d-Ino to FUra resulted in an accumulation of FdUMP with increased TS inhibition.

Because cancer now is more considered as a matter of deficiency of apoptosis rather than proliferative cells, involvement of anticancer drugs in apoptosis is a key issue in today’s chemotherapy (40) . Our data highlight the apoptosis-inducing potential of FUra via its active FdUMP metabolite through the Fas system. In addition, the insensitivity of CaCo2 cells to the modulation of FUra by d-Ino underlines the critical role cell death signaling plays in the response to fluoropyrimidine treatment. Although FdUMP accumulation and near total TS inhibition was achieved by modulating FUra conversion, the absence of Fas CD95 protein on the CaCo2 surface prevents the drug from exhibiting stronger antiproliferative action.

The feasibility of using d-Ino combined to FUra in vivo was next investigated in SW620-bearing nude mice. Because high levels of erythrocytic purine nucleoside phosphorylase could catabolize d-Ino before it reaches the tumor tissue (41) , elevated but well-tolerated doses of d-Ino were administered to the animals. Although doses and treatment schedule were chosen empirically, our data showed that combining d-Ino to FUra significantly reduced tumor growth, whereas FUra alone has little but no effect.

Our results indicate that FUra efficacy can be improved both in vitro and in vivo by modulating the way the drug is converted after cellular uptake, and that direct formation of FdUMP via TP leads to increase cytotoxicity as long as tumor cells are sensitive to Fas-mediated apoptosis. Several studies revealed the role of TP in neoangiogenesis (42, 43, 44) , underlining the dual role TP plays in treatment of colorectal cancer by fluoropyrimidines (45, 46, 47) . Because it has been reported that TP exerts its angiogenic properties by catalytic action on thymidine to release chemoattractant and angiogenesis-inducing factors (48) , increasing TP activity in its phosphorylase way only with d-Ino should not promote the development of angiogenesis.

It is commonly acknowledged that the main origin of TS-directed FdUMP metabolite comes from the reduction of FUDP by ribonucleotide reductase after prior conversion of FUra to FUDP via uridine phosphorylase or orotate phosphorylase transferase. Because several studies suggest that FUra could exert an higher cytotoxic activity when converted directly to FdUMP from FdUrd via TP, we assessed in this work to what extent d-Ino, a dR1P donor increasing TP activity, could affect FUra cellular pharmacology. We showed that d-Ino induces FdUMP accumulation with enhancement of both early and late apoptosis in a Fas-dependent manner, and that resistance of the SW620 line could be overcome in vitro and in vivo by combining the two drugs. Although the mechanism by which cell death is mediated in cells exposed to FUra is still not fully understood, our data show that there is a strong correlation between FdUMP accumulation and Fas expression. Complementary studies will have to be carried out to optimize treatment schedule and to fully confirm the mechanism of action of d-Ino when combined to FUra in vivo.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Ligue Nationale Contre le Cancer and Ligue Departementale, Comite du Var, Contre le Cancer. This work was presented, in part, at the AACR 90th Meeting, Philadelphia, Pennsylvania 1999. Back

2 To whom requests for reprints should be addressed, at Laboratoire de Toxicocinetique et Pharmacocinetique, Faculte de Pharmacie, 27 Bd Jean Moulin 13385, Marseille Cedex 05, France. Phone: 33-4-91-83-55-41; Fax: 33-4-91-83-56-67; E-mail: joseph.ciccolini{at}pharmacie.univ-mrs.fr Back

3 The abbreviations used are: FUra, 5-fluorouracil; FdUrd, 5-fluorodeoxyuridine; FdUMP, fluorodeoxyuridine monophosphate; FUDP, fluorouridine diphosphate; FUTP, fluorouridine triphosphate; d-Ino, 2'-deoxyinosine; MoAb, monoclonal antibody; TP, thymidine phosphorylase; TS, thymidylate synthase; dR1P, deoxyribose 1-phosphate; HPLC, high-performance liquid chromatography; FACS, fluorescence-activated cell sorter. Back

Received 10/11/99; revised 1/21/00; accepted 1/21/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Heidelberger C., Chaudhuri N. K., Danneberg P., Mooren D., Greisbach L., Duschnisky R., Schnitzer R. J., Pleven E., Scheiner J. Fluorinated pyrimidines, a new class of tumor inhibiting compounds. Nature (Lond.), 179: 663-666, 1957.[CrossRef][Medline]
  2. Cohen A. M., Minsky B. D., Schilsky R. L. Colon cancer Ed. 4 Devita V. T. Hellman S. Rosenberg S. A. eds. . Cancer, Principles and Practices in Oncology, : 929-971, J. B. Lippincott Co. Philadelphia 1993.
  3. Parker W. B., Cheng Y. C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther., 48: 381-395, 1990.[CrossRef][Medline]
  4. Rustum Y. M., Harstrick A., Cao S., Vanhoefer U., Yin M. B., Wilke H., Seeber S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol., 15: 389-400, 1997.[Abstract/Free Full Text]
  5. Sobrero A. F., Aschele C., Bertino J. R. Fluorouracil in colorectal cancer–a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol., 15: 368-381, 1997.[Abstract/Free Full Text]
  6. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol. Ther., 50: 367-424, 1991.[CrossRef][Medline]
  7. Gotto A. M., Belkhode M. L., Touster O. Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14C, 5-fluorouracil-2-14C, and 5-bromouracil-2-14C into nucleic acids by Ehrlich ascites tumor cells in vitro. Cancer Res., 29: 807-811, 1969.[Abstract/Free Full Text]
  8. Kessel D., Hall T. C. Influence of ribose donors on the action of 5-fluorouracil. Cancer Res., 29: 1749-1754, 1969.[Abstract/Free Full Text]
  9. Evans R. M., Laskin J. D., Hakala M. T. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res., 41: 3288-3295, 1981.[Medline]
  10. Schwartz E. L., Baptiste N., Megati S., Wadler S., Otter B. A. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res., 55: 3543-3550, 1995.[Abstract/Free Full Text]
  11. Schwartz E. L., Hoffman M., O’Connor C. J., Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-{alpha} in human colon carcinoma cells. Biochem. Biophys. Res. Commun., 182: 1232-1239, 1992.[CrossRef][Medline]
  12. Patterson A. V., Zhang H., Maghaddam A., Bicknell T., Talbot D. C., Straford I. J., Harris A. L. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-desoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer, 72: 669-675, 1995.[Medline]
  13. Evrard A., Cuq P., Robert B., Vian L., Pelegrin A., Cano J. P. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int. J. Cancer, 80: 465-470, 1999.[CrossRef][Medline]
  14. Evrard A., Cuq P., Ciccolini J., Vian L., Cano J. P. Increased cytotoxicity and bystander effect of FUra and 5'-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br. J. Cancer, 80: 1726-1733, 1999.[CrossRef][Medline]
  15. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.[Abstract/Free Full Text]
  16. Chazal M., Cheradame S., Formento J. L., Francoual M., Formento P., Etienne M. C., Francois E., Richelme H., Mousseau M., Letoublon C., Pezet D., Cure H., Seitz J. F., Milano G. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. Clin. Cancer Res., 3: 553-557, 1997.[Abstract]
  17. Roberts D. An isotopic assay for thymidylate synthetase. Biochemistry, 5: 3546-3548, 1966.[CrossRef][Medline]
  18. Grem, L. G., and Collins, J. M. Fluorinated pyrimidines. In: Cancer Chemotherapy: Principles and Practice, pp. 180–224. New York: J. B. Lippincott Co., 1990.
  19. Myers C. E., Young R. C., Chabner B. A. Biochemical determinants of FUra response in vivo: the role of deoxyuridylate pool expansion. J. Clin. Investig., 56: 1231-1238, 1975.
  20. Myers C. E., Diasio R., Eliot H. H., Chabner B. A. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. Cancer Treat. Rep., 3: 175-183, 1976.[CrossRef]
  21. Klubes P., Leyland-Jones B. Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue. Pharmacol. Ther., 41: 289-302, 1989.[CrossRef][Medline]
  22. Pritchard D. M., Watson A. J., Potten C. S., Jackman A. L., Hickman J. A. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA, 94: 1795-1799, 1997.[Abstract/Free Full Text]
  23. Geoffroy F. J., Allegra C. J., Sinha B., Grem J. L. Enhanced cytotoxicity with interleukin-1{alpha} and 5-fluorouracil in HCT116 colon cancer cells. Oncol. Res., 6: 581-591, 1994.[Medline]
  24. Kufe D. W., Major P. P 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem., 256: 9802-9805, 1981.[Abstract/Free Full Text]
  25. Heidelberger C., Danenberg P. V., Moran R. G. Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. Relat. Areas Mol. Biol., 54: 58-119, 1983.[Medline]
  26. Peters G. J., Laurensse E., Leyva A., Lankelma J., Pinedo H. M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res., 46: 20-28, 1986.[Abstract/Free Full Text]
  27. Piper A. A., Fox R. M. Biochemical basis for the differential sensitivity of human T- and B-lymphocyte lines to 5-fluorouracil. Cancer Res., 42: 3753-3760, 1982.[Abstract/Free Full Text]
  28. Barankiewicz J., Henderson J. F. Ribose 1-phosphate metabolism in Ehrlich ascites tumor cells in vitro. Biochim. Biophys. Acta, 479: 371-377, 1977.[Medline]
  29. Schwartz E. L., Baptiste N., O’Connor C. J., Wadler S., Otter B. A. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res., 54: 1472-1478, 1994.[Abstract/Free Full Text]
  30. Schwartz E. L., Baptiste N., Wadler S., Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem., 270: 19073-19077, 1995.[Abstract/Free Full Text]
  31. Friedkin M., Roberts D. The enzymatic synthesis of nucleosides. II. Thymidine and related pyrimidine nucleosides. J. Biol. Chem., 207: 257-266, 1954.[Free Full Text]
  32. Santelli G., Valeriote F. In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J. Natl. Cancer Inst., 64: 69-72, 1980.
  33. Houghton J. A., Harwood F. G., Gibson A. A., Tillman D. M. The Fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin. Cancer Res., 1: 723-730, 1997.[Abstract]
  34. Houghton J. A., Harwood F. G., Tillman D. M. Thymineless death in colon carcinoma cells is mediated via Fas signaling. Proc. Natl. Acad. Sci. USA, 94: 8144-8149, 1997.[Abstract/Free Full Text]
  35. Koshiji M., Adachi Y., Taketani S., Takeuchi K., Hioki K., Ikehara S. Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-{gamma}. Biochem. Biophys. Res. Commun., 240: 376-381, 1997.[CrossRef][Medline]
  36. Piazza G. A., Rahm A. K., Finn T. S., Fryer B. H., Li H., Stoumen A. L., Pamukcu R., Ahnen D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.[Abstract/Free Full Text]
  37. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S. L., Galle P. R., Stremmel W., Oren M., Krammer P. H. p53 activates the CD95 (APO-1/fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 11: 2033-2045, 1998.
  38. Jiang S., Song M. J., Shin E. C., Lee M. O., Kim S. J., Park J. H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology, 29: 101-110, 1999.[CrossRef][Medline]
  39. Tillman D. M., Petak I., Houghton J. A. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res., 5: 425-430, 1999.[Abstract/Free Full Text]
  40. Guchelaar H. J., Vermes A., Vermes I., Haanen C. Apoptosis molecular mechanisms and implications for cancer chemotherapy. Pharm. World Sci., 19: 119-125, 1997.[CrossRef][Medline]
  41. Lionetti F. J., Fortier N. L. Metabolism of deoxyinosine by human erythrocyte ghosts. Biochim. Biophys. Acta, 119: 462-469, 1966.[Medline]
  42. Folkman J. What is the role of thymidine phosphorylase in tumor angiogenesis. J. Natl. Cancer Inst., 88: 1091-1092, 1996.[Free Full Text]
  43. Schwartz E. L., Wan E., Wang F. S., Baptiste N. Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res., 58: 1551-1557, 1998.[Abstract/Free Full Text]
  44. Takahashi Y., Bucana C. D., Akagi Y., Liu W., Cleary K. R., Mai M., Ellis L. M. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin. Cancer Res., 4: 429-434, 1998.[Abstract/Free Full Text]
  45. Makower D., Wadler S., Haynes H., Schwartz E. L. Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin. Cancer. Res., 6: 923-929, 1997.
  46. Marchetti S., Fischel J. L., Pierrefite V., Mala M., Rostagno P., Etienne M. C., Milano G. Thymidine phosphorylase (TP): a dual role in the pharmacology of fluoropyrimidine prodrugs and tumoral angiogenesis. Proc. Am. Assoc. Cancer Res., 40: 518 1999.
  47. Metzger R., Danenberg K., Leichman C. G., Salonga D., Schwartz E. L., Wadler S., Lenz H. J., Groshen S., Leichman L., Danenberg P. V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res., 10: 2371-2376, 1998.
  48. Brown N. S., Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem. J., 334: 1-8, 1998.



This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
J. Friedrich, W. Eder, J. Castaneda, M. Doss, E. Huber, R. Ebner, and L. A. Kunz-Schughart
A Reliable Tool to Determine Cell Viability in Complex 3-D Culture: The Acid Phosphatase Assay
J Biomol Screen, October 1, 2007; 12(7): 925 - 937.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Magne, J.-L. Fischel, A. Dubreuil, P. Formento, J. Ciccolini, J.-L. Formento, C. Tiffon, N. Renee, S. Marchetti, M.-C. Etienne, et al.
ZD1839 (Iressa) Modifies the Activity of Key Enzymes Linked to Fluoropyrimidine Activity: Rational Basis for a New Combination Therapy with Capecitabine
Clin. Cancer Res., October 15, 2003; 9(13): 4735 - 4742.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Alimonti, G. Ferretti, S. Di Cosimo, F. Cognetti, and A. Vecchione
Can Colorectal Cancer Patients With Thymidylate Synthase-Overexpressing Liver Metastases Have an Overall Survival Advantage With Hepatic Arterial Infusion Alone?
J. Clin. Oncol., September 15, 2003; 21(18): 3543 - 3544.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ciccolini, F. Fina, K. Bezulier, S. Giacometti, M. Roussel, A. Evrard, P. Cuq, S. Romain, P.-M. Martin, and C. Aubert
Transmission of Apoptosis in Human Colorectal Tumor Cells Exposed to Capecitabine, Xeloda, Is Mediated via Fas
Mol. Cancer Ther., September 1, 2002; 1(11): 923 - 927.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ciccolini, P. Cuq, A. Evrard, S. Giacometti, A. Pelegrin, C. Aubert, J.-P. Cano, and A. Iliadis
Combination of Thymidine Phosphorylase Gene Transfer and Deoxyinosine Treatment Greatly Enhances 5-Fluorouracil Antitumor Activity in Vitro and in Vivo
Mol. Cancer Ther., December 1, 2001; 1(2): 133 - 139.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciccolini, J.
Right arrow Articles by Catalin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciccolini, J.
Right arrow Articles by Catalin, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online